Clinical trial
A Multicenter, Randomized, Controlled, Non-inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple Myeloma
NCT06314698 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Controlled, Non-inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple Myeloma
- Lead sponsor
- RenJi Hospital
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- April 1, 2024
- Completion date
- April 30, 2027
- Enrollment
- 478 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.